A clinical trial testing the oral therapy tebapivat for sickle cell disease is fully enrolled, with early results expected later this year.

Recent therapies like hydroxyurea (Droxia, Bristol-Myers Squibb), the first FDA-approved drug for SCD in 1994, increase fetal hemoglobin (HbF), which, through unknown pathways, improves SCD symptoms ...

81.7% of patients were on an SGLT2 inhibitor 74.7% of patients were on an ARNI 95.1% of patients were on a beta-blocker 83.1% of patients were on an MRA Despite high use of GDMT, the rate of ...

LMP Capital and Income Fund offers an 8% dividend yield, focusing on income through diverse investments in MLPs, REITs, and common stocks. SCD's strategy includes a mix of energy and tech stocks, ...

LMP Capital and Income Fund offers a 9.7% yield, focusing on income generation through a diversified asset mix, but has underperformed recently. SCD trades at an 8.68% discount to NAV, yet remains ...

Scribe Therapeutics Co-Founder, President and CEO Benjamin L. Oakes, PhD A growing landscape for sickle cell disease (SCD) treatments, a growing relationship between the companies, and the potential ...

A new report based on patient focus groups suggests many clinicians can do more to help patients with sickle cell disease (SCD) feel heard and understood. People with sickle cell disease (SCD) say a ...

Sickle cell disease (SCD) is a group of inherited red blood cell disorders. SCD is typically benign, meaning it is noncancerous. The Centers for Disease Control and Prevention (CDC) estimate that SCD ...

Because SCD can impair blood and oxygen delivery to any part of the body, it can cause a wide range of complications, including anemia, blood clots, and stroke. It can also damage organs, such as the ...

Eyelit Technologies (Eyelit), a leader in optimized planning, scheduling, and execution systems for manufacturers, today ...